Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label bapineuzumab in Alzheimer's disease (extension of AAB-001-201/202/102)
2006-004675-35Phase 2Terminated
- Sponsor
- Elan Regulatory Holdings
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Elan Regulatory Holdings. Primary endpoint: Treatment-emergent adverse events. Started Jul 2007; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-004675-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004675-35.